Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)

What Was Tested

Researchers studied Anamorelin (non-peptide) in this randomized controlled trial publication.

Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer.

Who Took Part

According to the abstract, 174 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This double-blind clinical trial (ONO-7643-04) enrolled 174 patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) and cachexia in Japan.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Anamorelin (non-peptide) group and the comparison group should start out alike.

As a double-blind Anamorelin (non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Anamorelin (non-peptide) could be set against what happens without it.

The methods mention a period of 12 weeks.

The primary endpoint was the change from the baseline LBM (measured with dual-energy x-ray absorptiometry) over 12 weeks.

The secondary endpoints were changes in appetite, body weight, quality of life, handgrip strength (HGS), and 6-minute walk test (6MWT) results.

What Was Measured

PubMed files the paper under topics including Body Composition, Cachexia, Carcinoma, Non-Small-Cell Lung, Hydrazines, Lung Neoplasms and Oligopeptides.

The authors tagged it with the keywords anamorelin (ONO-7643), lean body mass, non-small cell lung cancer and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Anamorelin (non-peptide) in 174 patients over 12 weeks.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Cancer), a journal based in United States.

More context: the Anamorelin (non-peptide) compound page, all human trials.